Role of β−lactamase in the susceptibility of clinical isolates to β−lactam antibiotics.
dc.contributor.author | Soebandrio, A | |
dc.contributor.author | Sri-Budayanti, N N | |
dc.contributor.author | Widayati, A | |
dc.contributor.author | Wiwing, V | |
dc.contributor.author | Nusatya, M A C M | |
dc.date.accessioned | 2013-11-11T04:04:52Z | |
dc.date.available | 2013-11-11T04:04:52Z | |
dc.date.issued | 2004-07 | |
dc.description.abstract | Combination of β−lactam antibiotic with β−lactamase inhibitor has been proven to overcome resistance caused by β−lactamase production. An evaluation to the MIC of some β−lactam antibiotics to β−lactamase producing isolates will be reported. A. anitratus, E. coli, K. pneumoniae, Proteus sp, Pseudomonas sp, S. aureus, S. epidermidis, S. pneumoniae, S. viridans, and β−hemolytic Streptococcus, were challenged to Ampicillin/Sulbactam (AMS), Amoxicillin/Clavulanic acid (AMC), Cefoperazone (CFP), Cefoperazone/Sulbactam (CSL), Ceftriaxone (CRO), dan Cefotaxime (CTX) using ETest techniques. β−lactamase production was identified using Cefinase disk. Sixtyfour percent of isolates were capable of producing β−lactamase. All E. coli and K. pneumoniae tested were β−lactamase producer, none of Proteus sp, Pseudomonas sp, and S. epidermidis tested produced β−lactamase. In β−lactamase producing group, Sulbactam was able to reduce resistance to CFP from 25% to 5%. About 20% of β−lactamase producing isolates which were resistant to CFP, were susceptible to CSL. Susceptibility of S.viridans to AMS, AMC, CFP, and CSL was higher than 80%, but less than 50% to CRO and CTX. S. pneumoniae was less susceptible to tested antibiotics, 50 to 60% susceptibility was shown to AMC, CFP, and CSL. S.aureus was 60 to 70% susceptible, while β−haemolytic Streptococcus showed good response to the tested antibiotics. Only 30% or less of K. pneumoniae and E. coli was susceptible to AMS and AMC. A. anitratus showed good susceptibility only to AMS (78%) and CSL (89%). Sixtyfour percent of isolate studied produced β−lactamase. β−lactamase inhibitor could reduce resistance of β−lactamase producing organism to β−lactam antibiotic from 25 to 5 percent. | en_US |
dc.identifier.citation | Soebandrio A, Sri-Budayanti N N, Widayati A, Wiwing V, Nusatya M A C M. Role of β−lactamase in the susceptibility of clinical isolates to β−lactam antibiotics. Medical Journal of Indonesia. 2004 July; 13(3): 140-145. | en_US |
dc.identifier.uri | https://imsear.searo.who.int/handle/123456789/149203 | |
dc.language.iso | en | en_US |
dc.source.uri | https://mji.ui.ac.id/journal/index.php/mji/article/view/147 | en_US |
dc.subject | Antibiotic Susceptibility | en_US |
dc.subject | MIC | en_US |
dc.subject | β−lactam antibiotic | en_US |
dc.subject | β−lactamase inhibitor | en_US |
dc.subject.mesh | Anti-Bacterial Agents | en_US |
dc.title | Role of β−lactamase in the susceptibility of clinical isolates to β−lactam antibiotics. | en_US |
dc.type | Article | en_US |